ArticleScience (New York, N.Y.)2024
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.Nature medicine · 2026Trial
- Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.The oncologist · 2025Trial
- TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.The Journal of experimental medicine · 2026Article
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Evolving precision: Updates in targeted therapy for cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Review
- Viral mimicry escape as a necessary feature of malignant transformation.Nature reviews. Cancer · 2026Review
- Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth.Cell · 2026Article
- APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations.Molecular oncology · 2026Article
- Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies.Molecular cancer · 2026Review
- DNA Methylation Profiling in IDH-Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation.Neuropathology and applied neurobiology · 2026Review
- IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Nature cancer · 2026Article
- Article
- Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Article
- The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers · 2026Review
- Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.JCI insight · 2026Article
- Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.The oncologist · 2026Article
- Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates.Nature chemistry · 2026Article
- Metabolites as signalling molecules in the tumour immune microenvironment.Nature reviews. Immunology · 2026Review
- Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer.Molecular cancer · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors.
Meng-Ju Wu *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0001-6847-7065
Hiroshi Kondo *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0003-0001-9492
Ashwin V Kammula *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0001-5284-721X
Lei ShiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0003-1149-0474
Yi XiaoChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-3817-3471
Sofiene DhiabKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0009-0009-1344-6275
Qin XuKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-5860-8225
Chloe J SlaterKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0001-8493-6583
Omar I AvilaKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-3853-9939
Joshua MerrittKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0009-0006-1306-7791
Hiroyuki KatoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0003-0655-1519
Prabhat KattelKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.
Jonathan SussmanAbramson Family Cancer Research Institute and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-3057-3550
Ilaria GrittiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-7313-0450
Jason EcclestonAbramson Family Cancer Research Institute and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Yi SunKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0009-0003-1720-8844
Hyo Min ChoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.
Kira OlanderBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3356-7631
Takeshi KatsudaAbramson Family Cancer Research Institute and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0003-3960-033X
Diana D ShiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Milan R SavaniChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-1776-451X
Bailey C SmithChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0009-0001-4719-4581
James M Cleary
Raul MostoslavskyKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-7740-5212
Vindhya VijayKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-7886-7443
Yosuke KitagawaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1903-1283
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8225-241X
Russell W JenkinsKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0001-6110-2148
Kathleen B YatesKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0002-7383-5573
Jihye PaikDepartment of Pathology and Laboratory Medicine, Sandra and Edward Meyer Cancer Center, Weill Medical College of Cornell University, New York, NY, USA.ORCID 0000-0002-5481-2202
Ania TassinariServier Pharmaceuticals LLC, Boston, MA, USA.ORCID 0000-0002-1077-3141
Duygu Hatice SaatciogluServier Pharmaceuticals LLC, Boston, MA, USA.ORCID 0000-0003-2210-0005
Adriana E TronServier Pharmaceuticals LLC, Boston, MA, USA.ORCID 0000-0001-9506-2121
Wilhelm HaasKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0001-8225-9099
Daniel CahillDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2552-6546
Samuel K McBrayerChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9361-675X
Robert T MangusoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0003-1336-413X
Nabeel BardeesyKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.ORCID 0000-0003-3867-0416
Funding
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MTargeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WENDY Beth LONDON · 2013 to 2026
$33.5MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MTargeting the neuronal microenvironment in glioblastomaU19CA264504 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Tracy T Batchelor · 2021 to 2026
$6.4MTargeting novel therapeutic vulnerabilities in LKB1 mutant tumors.R01CA219670 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, WONG, KWOK KIN · 2018 to 2022
$3.4MMechanistic Understanding for the Role of Lin28b in Pancreatic Cancer ProgressionR01CA235412 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, MOSTOSLAVSKY, RAUL · 2019 to 2023
$3.2MFunctions of the LKB1 tumor suppressor in control in metabolism and epigenticsR01CA215498 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL · 2018 to 2022
$2.7MFunctions of mutant IDH in cholangiocarcinomaR01CA280085 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY · 2023 to 2026
$2.6MExploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma TherapyR01CA258586 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ABDULLAH, KALIL G, MCBRAYER, SAMUEL KENT · 2021 to 2025
$1.8MNovel Approaches to Modeling and Treating IDH1 Mutant GliomaK22CA237752 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MCBRAYER, SAMUEL KENT · 2019 to 2021
$494kExploiting metabolic reprogramming to target IDH1 mutated cholangiocarcinomaK99CA245194 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SHI, LEI · 2020 to 2021
$356kDefining mechanisms of metabolic-epigenetic crosstalk that drive glioma initiationK99CA277576 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI XIAO, YI · 2023 to 2024
$248kNCI NIH HHS F30 CA271634NCI NIH HHS K22 CA237752NCI NIH HHS K99 CA245194NCI NIH HHS K99 CA277576NCI NIH HHS P01 CA117969NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA215498NCI NIH HHS R01 CA219670NCI NIH HHS R01 CA235412NCI NIH HHS R01 CA258586NCI NIH HHS R01 CA280085NCI NIH HHS U19 CA264504
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immune EvasionImmunity, InnateIsocitrate DehydrogenaseNeoplasmsAnimalsCell Line, TumorCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNADNA DemethylationDNA MethylationDNA Transposable ElementsEpigenesis, GeneticGlutaratesHumansMiceMutationalpha-hydroxyglutaratecGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNADNA Transposable ElementsGlutaratesIDH1 protein, humanIdh1 protein, mouseIsocitrate DehydrogenaseNucleotidyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.